RxDoctor Payments Data

Travis Hanson, MD

Pulmonary Disease · Sioux Falls, SDNPI 1700197498

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $279 of the $325 with a category attached, or 85.8%. 7 manufacturers reported payments, led by GSK at 43.4% of the total. Reporting peaked in 2023 at $129 and has fallen 70.2% since, to $38 in 2025. That places this record below the midpoint for pulmonary disease clinicians in SD, where the typical reported total is $424.

$325in general payments, 2019–2025

Across 25 payments — averaging $13.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$141
  • Intuitive Surgical$86
  • Insmed, Inc.$34
  • Inspire Medical Systems, Inc.$21
  • Sanofi$18
  • Merck$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$27986%
  • Education$4614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 45th percentile of 35 pulmonary disease providers in South Dakota.

See all pulmonary disease providers in South Dakota

Medicare billing

Part B allowed, 2024
$79,039
Medicare patients
457
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate22$253,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter283$179,791
GlassiaAlpha-1-Proteinase Inhibitor13$173,364
NucalaMepolizumab15$166,474
Dupixent PenDupilumab19$67,393
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr120$65,126
Breo ElliptaFluticasone/Vilanterol148$60,824
Stiolto RespimatTiotropium Br/Olodaterol Hcl94$46,915
Spiriva RespimatTiotropium Bromide70$41,196
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$31,924
Incruse ElliptaUmeclidinium Bromide76$28,825
Pirfenidone23$25,314
DuleraMometasone/Formoterol74$25,019
Arnuity ElliptaFluticasone Furoate71$17,238
SymbicortBudesonide/Formoterol Fumarate31$10,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$141$518,278713 claims
MerckDulera$13$25,01974 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 pulmonary disease providers in South Dakota.

Other pulmonary disease in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →